Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to advance this first-in-class multiple sclerosis (MS) candidate into Phase 2 clinical development. The approval, disclosed on August 10, 2026, paves the way for a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures.
The significance of this milestone lies in Lucid-MS’s mechanism of action, which differs fundamentally from existing MS therapies. While current treatments primarily target the immune system to reduce inflammation and demyelination, Lucid-MS aims to provide neuroprotection by directly inhibiting demyelination. It targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have shown that Lucid-MS can prevent and even reverse myelin breakdown, a critical factor in MS progression. This approach could potentially offer a disease-modifying therapy that not only halts but also repairs the damage caused by MS, addressing a major unmet need in the field.
The Phase 2 trial will build on the safety data from earlier Phase 1 studies, where Lucid-MS was reported to be well tolerated in healthy participants. The company has stated that trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible. This expedited timeline suggests a strong commitment to bringing this potential therapy to patients.
Financially, Quantum BioPharma appears positioned to support the trial, reporting more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026. This funding is crucial for the costly process of clinical development, especially for a Phase 2 study that will require significant resources over an extended period.
The broader implications of this FDA clearance are substantial for the MS community. If Lucid-MS proves effective in Phase 2 and subsequent trials, it could represent a paradigm shift in how MS is treated, moving beyond immune modulation to direct neuroprotection and myelin repair. For Quantum BioPharma, this approval is a key validation of its pipeline and a step forward in its mission to develop innovative treatments for neurodegenerative disorders. The company, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on advancing Lucid-MS, which is a patented new chemical entity designed to address the underlying mechanism of MS.
In addition to its MS program, Quantum BioPharma has interests in other areas, including a stake in Unbuzzd Wellness Inc., which markets an OTC hangover remedy. The company retains a 19.84% ownership in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until a total of $250 million is reached, after which the royalty drops to 3% in perpetuity. This diversification provides additional revenue streams that could support ongoing research and development.
The full press release is available at https://ibn.fm/HyWYH. For more information on the company and its recent updates, visit the newsroom at https://ibn.fm/QNTM. As with all forward-looking statements, the company cautions that actual results may differ materially from those expressed or implied, and details on risk factors are outlined in their SEC filings.
